Production (Stage)
COSCIENS Biopharma Inc.
CSCI
$3.68
$0.113.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -160.89% | -190.57% | -65.35% | -65.35% | -391.58% |
| Total Depreciation and Amortization | -9.47% | -70.24% | 4.14% | 4.14% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 132.63% | 333.82% | -1,026.04% | -1,026.04% | -1,895.24% |
| Change in Net Operating Assets | 238.09% | -50.17% | 1,578.05% | 1,578.05% | -4.00% |
| Cash from Operations | 21.01% | -132.75% | -70.85% | -70.85% | -187.09% |
| Capital Expenditure | -9.04% | 56.36% | -190.74% | -190.74% | -1,719.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00% | -- | -- | -- |
| Cash from Investing | -9.04% | 55.80% | 48,025.93% | 48,025.93% | -1,719.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -112.77% | 57.59% | -80.00% | -80.00% | -46.88% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -112.77% | 17.21% | -80.00% | -80.00% | -49.21% |
| Foreign Exchange rate Adjustments | 144.78% | -160.27% | -137.22% | -137.22% | -578.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.93% | -143.21% | 3,309.78% | 3,309.78% | -254.41% |